University of Houston-founded company secures $2.5M in NIH grant funding

all in the timing

CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding. Photo via Getty Images

You could say that the booming success of Houston biotech company CellChorus owes very much to auspicious TIMING. Those six letters stand for Time-lapse Imaging Microscopy In Nanowell Grids, a platform for dynamic single-cell analysis.

This week, CellChorus announced that the company, along with The University of Houston, has been awarded up to $2.5 million in funding from the National Center for Advancing Translational Sciences (NCATS) at the National Institute of Health. A $350,000 Phase I grant is already underway. Once predetermined milestones are achieved, this will lead to a two-year $2.1 million Phase II grant.

The TIMING platform was created by UH Single Cell Lab researchers Navin Varadarajan and Badri Roysam. TIMING generates high-throughput in-vitro assays that quantitatively profile interactions between cells on a large scale, particularly what happens when immune cells confront target cells. This has been especially useful in the realm of immuno-oncology, where it has demonstrated its power in designing novel therapies, selecting lead candidates for clinical trials and evaluating the potency of manufactured cells.

“By combining AI, microscale manufacturing and advanced microscopy, the TIMING platform yields deep insight into cellular behaviors that directly impact human disease and new classes of therapeutics,” says Rebecca Berdeaux, chief scientific officer at CellChorus. “The generous support of NCATS enables our development of computational tools that will ultimately integrate single-cell dynamic functional analysis of cell behavior with intracellular signaling events.”

Houston’s CellChorus Innovation Lab supports both the further development of TIMING and projects for early-access customers. Those customers include top-25 biopharmaceutical companies, venture-backed biotechnology companies, a leading comprehensive cancer center and a top pediatric hospital, says CEO Daniel Meyer.

CellChorus’s publications include papers written in collaboration with researchers from the Baylor College of Medicine, Houston Methodist, MD Anderson, Texas Children’s Hospital, the University of Texas and UTHealth in journals including Nature Cancer, Journal of Clinical Investigation and The Journal for ImmunoTherapy of Cancer.

The new Small Business Technology Transfer (STTR) award will specifically support the development of a scalable integrated software system conceived with the goal of analyzing cells that are not fluorescently labeled. This label-free analysis will be based on new AI and machine learning (ML) models trained on tens of millions of images of cells.

“This is an opportunity to leverage artificial intelligence methods for advancing the life sciences,” says Roysam. “We are especially excited about its applications to advancing cell-based immunotherapy to treat cancer and other diseases.”

The Houston-born-and-bred company couldn’t have a more appropriate home, says Meyer.

“Houston is a premier location for clinical care and the development of biotechnology and life sciences technologies. In particular, Houston has established itself as a leader in the development and delivery of immune cell-based therapies,” the CEO explains. “As a spin-out from the Single Cell Lab at the University of Houston, we benefit from working with world-class experts at local institutions.”

In May, the company received a similar $2.5 million SBIR grant from NCATS at the NIH. Also this summer, CellChorus's technology was featured in Nature Cancer.

From Your Site Articles
The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia, one of the most common childhood cancers. Photo via Getty Images

Houston startup scores $12M grant to support clinical evaluation of cancer-fighting drug

fresh funding

Allterum Therapeutics, a Houston biopharmaceutical company, has been awarded a $12 million product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT).

The funds will support the clinical evaluation of a therapeutic antibody that targets acute lymphoblastic leukemia (ALL), one of the most common childhood cancers.

However, CEO and President Atul Varadhachary, who's also the managing director of Fannin Innovation, tells InnovationMap, “Our mission has grown much beyond ALL.”

The antibody, called 4A10, was invented by Scott Durum PhD and his team at the National Cancer Institute (NCI). Licensed exclusively by Allterum, a company launched by Fannin, 4A10 is a novel immunotherapy that utilizes a patient’s own immune system to locate and kill cancer cells.

Varadhachary explained that while about 80 percent of patients afflicted with ALL have the B-cell version, the other 20 percent suffer from T-cell ALL.

“Because the TLL population is so small, there are really no approved, effective drugs for it. The last drug that was approved was 18 or 19 years ago,” the CEO-scientist said. 4A10 addresses this unmet need, but also goes beyond it.

Because 4A10 targets CD127, also known as the interleukin-7 receptor, it could be useful in the treatment of myriad cancers. In fact, the receptor is expressed not just in hematological cancers like ALL, but also solid tumors like breast, lung, and colorectal cancers. There’s also “robust data,” according to Varadhachary for the antibody’s success against B-cell ALL, as well as many other cancers.

“Now what we're doing in parallel with doing the development for ALL is that we're continuing to do additional preclinical work in these other indications, and then at some point, we will raise a series A financing that will allow us to expand markets into things which are much more commercially attractive,” Varadhachary explains.

Why did they go for the less commercially viable application first? As Varadhachary put it, “The Fannin model is to allow us to go after areas which are major unmet medical needs, even if they are not necessarily as attractive on a commercial basis.”

But betting on a less common malady could have a bigger payoff than the Allterum team originally expected.

Before the new CPRIT grant, Allterum’s funding included a previous seed grant from CPRIT of $3 million. Other funds included an SBIR grant from NCI, as well as another NCI program called NExT, which deals specifically with experimental therapies.

“To get an antibody from research into clinical testing takes about $10 million,” Varadhachary says. “It's an expensive proposition.”

With this, and other nontraditional financing, the company was able to take what Varadhachary called “a huge unmet medical need but a really tiny commercial market” and potentially help combat a raft of other childhood cancers.

“That's our vision. It's not economically hugely attractive, but we think it's important,” says Varadhachary.

Atul Varadhachary is the managing director of Fannin Innovation. Photo via LinkedIn

“This breakthrough technology has the potential to reshape the landscape of disease treatment and the future of research and development in the field of cell-based therapies." Photo via Getty Images

Rice lab cooks up breakthrough 'living pharmacy' research for potential cell therapy treatment

biotech innovation

Rice University’s Biotech Launchpad has created an electrocatalytic on-site oxygenator, or ecO2, that produces oxygen intended to keeps cells alive. The device works inside an implantable “living pharmacy,” which the Rice Biotech Launch Pad team believes will one day be able to administer and regulate therapeutics within a patient’s body.

Last week, Rice announced a peer-reviewed publication in Nature Communications detailing the development of the novel rechargeable device. The study is entitled “Electrocatalytic on-site oxygenation for transplanted cell-based-therapies.”

How will doctors use the “living pharmacy?” The cell-based therapies implanted could treat conditions that include endocrine disorders, autoimmune syndromes, cancers and neurological degeneration. One major challenge standing in the way of bringing the technology beyond the theoretical has been ensuring the survival of cells for extended periods, which is necessary to create effective treatments. Oxygenation of the cells is an important component to keeping them alive and healthy and the longer they remain so, the longer the therapeutics will be helpful.

Other treatments to deliver oxygen to cells are ungainly and more limited in terms of oxygen production and regulation. According to Omid Veiseh, associate professor of bioengineering and faculty director of the Rice Biotech Launch Pad, oxygen generation is achieved with the ecO2 through water splitting that is precisely regulated using a battery-powered, wirelessly controlled electronic system. New versions will have wireless charging, which means it could last a patient’s entire lifetime.

“Cell-based therapies could be used for replacing damaged tissues, for drug delivery or augmenting the body’s own healing mechanisms, thus opening opportunities in wound healing and treatments for obesity, diabetes and cancer, for example. Generating oxygen on site is critical for many of these ‘biohybrid’ cell therapies: We need many cells to have sufficient production of therapeutics from those cells, thus there is a high metabolic demand. Our approach would integrate the ecO2 device to generate oxygen from the water itself,” says Jonathan Rivnay of Northwestern University, who co-led the study with Tzahi Cohen-Karni of Carnegie Mellon University (CMU).

The study’s co-first authors are Northwestern’s Abhijith Surendran and CMU’s Inkyu Lee.

Northwestern leads the collaboration with Rice to produce therapeutics onsite within the device. The research supports a Defense Advanced Research Projects Agency (DARPA) cooperative agreement worth up to $33 million to develop the implantable “living pharmacy” to control the human body’s sleep and wake cycles.

“This breakthrough technology has the potential to reshape the landscape of disease treatment and the future of research and development in the field of cell-based therapies. We are working toward advancing this technology into the clinic to bring it one step closer to those in need,” says Veiseh.

A Houston health care company received the green light from the FDA to advance a treatment that's targeting a deadly cancer. Photo via Getty Images

Houston immunotherapy company achieves FDA designation for cancer-fighting vaccine

got the green light

The FDA has granted a Houston-based company a Fast Track designation.

Diakonos Oncology Corp. is a clinical-stage immuno-oncology company that has developed a unique dendritic cell vaccine, DOC1021. The vaccine targets glioblastoma multiforme (GBM), the most common and most lethal malignant brain tumor in adults. The aggressive tumors come with a life expectancy of about 15 months following diagnosis. About 7 percent of those diagnosed survive five years, while the 10-year outlook only sees a one-percent survival rate.

“The FDA’s decision acknowledges the potential of this new treatment approach for a very challenging disease,” Diakonos CEO Mike Wicks says in a press release. “Our protocol represents a first for cancer immunotherapy and could be viable for many types of cancers beyond GBM.”

FDA Fast Track designations are intended to expedite the haste with which drugs with early clinical promise are reviewed, likely taking them to market faster.

DOC1021 uses the body’s natural anti-viral immune response to fight GBM. The vaccine mimics viral infection with the patient’s cancer markers. Essentially, DOC1021 uses the body’s own natural ability to detect and eliminate infected cells.

The technology uses dendritic cells, white blood cells that are able to perceive threats, to its advantage. The unique cancer markers are loaded both internally and externally into the immune cells, just as they would simultaneously occur in a viral infection. The individualized treatment is administered through three precise injections that target deep cervical lymph node chains. By dosing this way, the immune responses are directed straight to the central nervous system.

The results have spoken for themselves: All of the patients who have tried the treatment have exceeded survival expectations. And just as importantly, DOC1021 appears to be extremely safe. No serious adverse effects have been reported.

“Because Phase I clinical trials are generally not statistically powered to demonstrate efficacy, detection of a statistically significant efficacy signal is very promising,” says William Decker, associate professor of immunology at Baylor College of Medicine and inventor of the DOC1021 technology.

The Phase 1 open-label trial of DOC1021 (NCT04552886) is currently taking place at both the University of Texas Health Science Center in Houston and at the MD Anderson Cancer Center at Cooper University Health Care in Camden, NJ. The trial is expected to complete this year.

New facility will accelerate investigational treatments in cancer, heart disease, neurological disorders and more. Photo courtesy of Houston Methodist

Houston Methodist opens new cellular therapeutics center

new to hou

Houston Methodist recently opened a new 5,000-square-foot lab that will focus on developing and producing lifesaving treatments through cell therapy, the hospital announced last week.

Named the Ann Kimball & John W. Johnson Center for Cellular Therapeutics after long-time supporters of the hospital, the lab is located in the Houston Methodist Outpatient Center in the Texas Medical Center. The space includes 1710 square feet of cleanroom space, a dedicated quality control laboratory, six production rooms, support spaces and more to help develop new cell therapies and investigational therapeutics.

The combination of the control laboratory and production rooms onsite are anticipated to help the hospital treat patients safely and more efficiently, according to the statement.

Work at the JCCT is slated to benefit medical research throughout Houston Methodist in the fields of cancer, cardiovascular, neurology, organ transplantation, orthopedics and gastroenterology treatment.

The new center is named for Ann Kimball and John W. Johnson, who contributed a gift that will go toward establishing the facility. Photo courtesy of Houston Methodist

According to a statement from the hospital, cell therapy is "one of the most promising treatment options available," with applications in treatment for cancer, heart disease, and neurological diseases like ALS, Alzheimer’s and Parkinson’s. The therapy requires that a patient is implanted with live cells provided by a donor or the patient themselves. These cells can help repair or rejuvenate damaged tissue or cells.

“Many diseases have limited or ineffective therapies, so there is a tremendous need and opportunity to bring transformative and restorative new treatments to patients through cell therapy,” distinguished neurologist Dr Stanley Appel, who will lead the center, said the statement. “Having a cellular therapy laboratory on-site at Houston Methodist has always been a part of our vision. The Johnson family’s generosity and support of this vision will give hope to countless patients battling neurodegenerative diseases and more.”

The Johnsons' gift also created a matching fund that supports cell therapy projects in all specialties at Houston Methodist. At press time, the fund had helped attract 51 donors, including 69-year-old Jack McClanahan, who suffers from ALS and was the first to donate to the center.

"I volunteered for this because I want a younger man or woman with children to have a chance – this is a devastating disease,” McClanahan said in the statement. “If there’s any hope to help others, I just want to be part of it.”

Houston Methodist also announced last month that it will break ground on a $650 million Cypress "smart" hospital this spring. The hospital is slated to incorporate artificial intelligence, big data, and Alexa- and Siri-like voice technology into its treatment plans and design.

A Houston biotech company has raised $38.1 million. Photo by Dwight C. Andrews/Greater Houston Convention and Visitors Bureau

Houston-based cancer and disease bio-venture launches after $38.1M series A

money moves

Sporos Bioventures LLC launched this month after closing a $38.1 million round of series A financing.

The Houston-based biotech company aims to accelerate the development of breakthrough therapies for cancer and immune diseases by sharing resources, capital, access to clinical trial infrastructure, and talent from within its knowledgeable team of biotech executives, entrepreneurs, academic scholars, and investors. The company was launched with four entities: Tvardi Therapeutics, Asylia Therapeutics, Nirogy Therapeutics, and Stellanova Therapeutics.

The most advanced of the four entities, Tvardi, is currently in Phase 1 clinical trial to evaluate it's STAT3 oral inhibitor. It was named a "most promising" life sciences company at the 2020 Texas Life Science Forum, hosted by BioHouston and the Rice Alliance in December. The remaining entities are in the development stages and are focused on cancer, autoimmune disease, fibrosis, and tumor growth, among other conditions.

"Sporos was founded to accelerate the development of new medicines by addressing inefficiencies and risk in the establishment of new biotech companies," Peter Feinberg, Sporos co-founder, said in a statement. "By leveraging our extensive network, including the Texas Medical Center, we first identify transformative scientific opportunities and then deploy our top-tier talent, funding, and operational support to drive these insights into a growing pipeline of first-in-class treatment options."

In conjunction with the launch, Sporos named Michael Wyzga as the company's founding CFO. Wyzga was previously CFO at Genzyme for 12 years and has held various senior-level positions in the industry.

"By strategically deploying valuable resources to young companies that would not typically be supported by top-tier seasoned talent and infrastructure, we believe that we can efficiently bring a diverse set of therapies through clinical development," Wyzga said in a statement. "I am thrilled to join a team with decades of scientific and operational expertise and look forward to guiding our strategic and financial growth."

Wyzga joins a team of seasoned leaders in the biotech and cancer research fields, including Dr. Ronald DePinho, professor of Cancer Biology and past president of MD Anderson, who will serve as the chair of Sporos' Strategic Advisory Council. Jeno Gyuris, a biotech executive in oncology drug discovery and development with more than 25 years of experience, will serve as chief science officer. And Alex Cranberg, an experienced active early-stage biotech investor, serves as director.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

2 Houston startups win big at SXSW 2025 pitch competition

winner, winner

Houston had a strong showing at this week's SXSW Pitch showcase in Austin, with two local startups claiming top prizes in their respective categories.

Little Place Labs, a Houston space data startup, won the Security, GovTech & Space competition. Clean-tech company Helix Earth, which spun out of Rice University and was incubated at Greentown Labs, won in the Smart Cities, Transportation & Sustainability contest.

As one of SWSX's marquee events, held March 8-10, the pitch competition featured 45 finalists, selected from 589 applicants, in nine categories.

"We faced impressive competition from a well-chosen set of finalists, and we're honored to be chosen as the winners. One of the judges even commented, ‘Who knew you could make air conditioning sexy,’” Brad Husick, Helix's co-founder and chief business officer, said in a release.

Helix Earth was launched in 2022 and is known for its space capsule air filtration system that was co-developed for NASA. The commercial air conditioner add-on technology, now in a pilot phase, has been used to retrofit HVAC systems for commercial buildings and can save up to 50 percent of the net energy, cutting down on emissions and operating costs, according to the company. Its co-founder and CEO Rawand Rasheed was named to the Forbes 30 Under 30 Energy and Green Tech list for 2025.

“This win validates our mission to drive sustainable innovation in commercial air conditioning and beyond. We are excited about the future of Helix Earth and the impact we will have in reducing energy consumption and emissions," Rasheed said in a statement.

Little Place Labs echoed that sentiment with a post on LinkedIn celebrating the win.

"This all started with a simple mission: To deliver real-time space insights to help first responders, mission planners, and decision-makers act before problems arise,” the post read. "Today, that mission feels even stronger."

The company uses advanced AI and machine learning to deliver near-real-time space analytics for both ground and space-based applications. Its software aims to help first responders, mission planners and decision-makers detect anomalies and make informed decisions quickly. It was co-founded in 2020 at Oxford by Houstonian and CEO Bosco Lai and Gaurav Bajaj and participated in the 2023 AWS Space Accelerator.

Two other Houston companies were selected as finalists:

  • Trez, a Latino-focused fintech company that uses AI and voice-command payroll through WhatsApp to provide culturally relevant payroll and streamline financial operations for Latino business owners.
  • Tempesst Droneworx, a veteran-owned software company that's Harbinger software providing real-time contextual intelligence for early warning detection, reducing time to decision and speeding time to action.

Jesse Martinez, founder of invincible, and Anu Puvvada of KPMG were two judges representing Houston.

According to SXSW, 647 companies have participated in SXSW Pitch over the years, with over 93 percent receiving funding and acquisitions totaling nearly $23.2 billion. See the full list of 2025 winners here.

A legacy of industrial technology excellence: UTSI International turns 40

Cheers to 40 Years

As UTSI International celebrates its 40th anniversary, president and CEO Shaun Six reflects on the company's history, achievements, and exciting future.

---

In March 1985, Dan Nagala and a few friends took a risk, leaving their full-time jobs to pursue their passion and start their own company.

They founded UTSI Internationalamidst groundbreaking advancements in Industrial Control Systems and SCADA technology, revolutionizing remote operations for critical infrastructure. From the start, UTSI has been at the forefront of OT innovation and integration — a legacy we proudly carry forward today.

The legacy of Dan Nagala

Dan Nagala’s 50-plus-year career is too vast to cover every accomplishment, but if you’ve ever heard the phrase “Houston, we have a problem” in a movie, those screens in the control room and the logic causing the “blinky lights” to alert the operators, you’ve seen some of his work. Dan and his team ultimately paved the way for field communications to detect and communicate leaks on pipelines and give operators in remote locations situational awareness, expanding their ability to safely monitor and control their operations.

This capability was requested early on in the first pipeline control rooms, leading to UTSI’s first check-in 1985 (which I proudly have framed on my bookshelf). The protocols to communicate and do advanced calculations — which many would be tempted to call AI today — for the purpose of monitoring and control, was created from this group of enthusiasts who open sourced it and allowed it to proliferate, leading to over 80 percent of all critical infrastructure in the world now utilizing a variant thereof.

Given the novelty of the technology and the experience of UTSI, having implemented control systems and automation for pipelines in over 22 countries, Dan was asked to collaborate with industry experts, creating the first API leak detection and control room management standards for the American Petroleum Institute. These would later become regulation under PHMSA, DoT, and TSA, placing UTSI as the go-to experts in compliance in addition to their traditional expertise.

UTSI has delivered for the world’s largest infrastructure owners in multiple critical infrastructure sectors, like mining, water/wastewater, oil and gas, green energy, transportation authorities, etc. We have also done AI and cybersecurity, in addition to SCADA and ICS work for the DoD and DoE.

Strength in partners

I joined UTSI in 2022 as vice president, working under Dan, with the goal of gradually stepping into leadership. In 2023, I became CEO, president, and majority shareholder. While no one can truly fill Dan’s shoes alone, we’ve focused on strengthening our team, partnerships, and capabilities to continue UTSI’s legacy of excellence.

One of our first strategic partnerships was with Tory Tech, a leading API-compliant Control Room Management tool. UTSI has worked as integrators with Tory Tech for years and Dan worked as a CRM compliance advisor for them in the U.S. while they were setting up their headquarters in Houston. In 2024 we made it an official partnership, becoming a preferred integrator and focusing our team on training and development in the MaCRoM (Master Control Room Management) tool.

We've also made significant investments in our OT cybersecurity capabilities, expanding our team and partnering with industry leaders like Dennis Parker, Derrik Oates, Nozomi Networks, Fortinet, and Schneider Electric. These strategic moves ensure we deliver top-tier expertise, products, and solutions to better serve our customers.

Our partnership with ThreatGEN and the utilization of their AI-driven “AutoTableTop” tool not only utilizes our experience with TSA guidelines, but adds an element of reality that the traditional methods are lacking, making these engagements more interactive and beneficial for operators who are required to participate annually.

In 2024, UTSI also invested heavily in AI and Data Science by acquiring Houston-based AI company Pandata Tech and leveraging their Data-Quality-Methodology (DQM), Leak Geek, and time-series data science expertise to solve industry specific problems.

Moving up – in and around Houston

Building on our recent successes, we strategically relocated our office to the Netrality building (1301 Fannin St.), bringing us closer to clients and partners, while getting access to a Tier 3 Data Center with an uninterrupted 40-year power record.

Netrality is a SOC2-compliant facility with seven points of detection from the street to our server, including biometric screening. Our very own Roberto deLeon has architected our upgraded servers using the Purdue model as a basis of design while leveraging our relationship with Fortinet to standardize our hardware and software to the highest standards. We practice what we preach — every architecture, framework, and hardware recommendation we make is not just advised but actively implemented within our own operations.

Our investment in this space includes increasing our “SCADA R&D Lab” to play with toys from vendors, testing them out in our environment before we recommend and advise them to our clients and partners. Currently we’re working on LLMs for OT, building our own “DANN2.0” for use in-house. DANN is an homage to Dan Nagala (and, for the nerds, stands for Dan Artificial Neural Network), which we started in 2022 when I realized that knowledge capture is an industry wide epidemic and we need to be ready to integrate for our clients in a safe and local way at scale, in the OT environment.

Additionally, having come from a startup before joining UTSI, I wanted to get us closer to the heart of innovation, so we’ve added additional office space at The Cannon downtown. While there are many tech hubs around Houston, and we are proud to work with and partner with companies from Greentown Labs and the Ion, to name a few, we’ve found that The Cannon community is incredibly active and innovative, with experience in industrial use-cases.

Houston is set to become the Energy Transition capital, leading in hydrogen, carbon capture, and repurposing. With a 5:1 ratio of engineers leaving the industry and an average age over 60, we must innovate. The solution lies in combining a secure, cloud-free "ChatGPT for OT" with digital twins. Bringing the field to engineers is essential. We've partnered with a satellite constellation for asset imaging and U.K.-based Mods Solutions to leverage their CFIHOS-driven platform for intelligent digital twins — more on that partnership soon!

And we will need to leverage enhanced automation tools and actively monitor control networks to ensure security and respond quickly to issues, which is why we’ve partnered with Nozomi Networks.

Shaping the future

Although Dan has semi-retired to his cabin in Montana, he continues to do “the fun stuff” that brings him joy, such as conducting research for PRCI and assisting long-time clients. He also has been a mentor and advisor to me since I started at UTSI three years ago. I’m grateful for him and the group of industry experts he gathered around him to make UTSI such a well-known systems integrator and OT advisor for the world’s largest asset owners.

Our group of experts are active in the industry and will be speaking at events throughout the year, with a presence at Entellec, Level Zero, and participating at this year's API Cybernetics and PSIGs biannual conferences. We proudly serve on the BCarbon advisory board and GHPs Energy Committee.

Lastly, we have one request: We see a critical need for H2 and supercritical CO2 studies to develop simulation models, response plans, and leak detection best practices. These gases differ from those covered in existing standards. If you know anyone interested in funding or contributing, we’re collaborating with industry partners to secure support.

Houston named No. 2 most diverse major U.S. city for 2025

Ranking It

Houston has always been a diverse place, embracing people of many different cultural and socioeconomic backgrounds. And the city is earning new recognition in WalletHub's rankings of the most diverse large American cities for 2025.

The 2025 edition is the final installment in WalletHub's diversity study series, which annually compared 501 U.S. cities across 13 metrics in five categories that encompass "diversity" across socioeconomic, cultural, economic, household, and religious factors.

Cities were also ranked by population, with large cities defined as those with over 300,000 residents, midsize cities with 100,000 to 300,000 residents, and small cities with fewer than 100,000 residents.

Houston nearly topped the list of large U.S. cities, coming in at No. 2, and ranked at No. 5 in the overall national comparison.

The top three most diverse American cities, which have held their positions for the second consecutive year, are all located in Maryland: Gaithersburg (No. 1), Silver Spring (No. 2), and Germantown (No. 3).

Houston performed spectacularly in the study's overall rankings for socioeconomic (No. 14), cultural (No. 32), and religious diversity (No. 63), but fell behind in the categories for household (No. 129) and economic diversity (No. 165).

In the more detailed comparisons across educational-attainment, linguistic, and industry diversity, Houston ranked among the top 30 in all three categories out of the 501 cities included in the report.

Here's how Houston performed across the remaining eight categories in the study:

  • No. 44 – Racial and ethnic diversity
  • No. 129 – Household type diversity
  • No. 200 – Household size diversity
  • No. 201 – Income diversity
  • No. 207 – Occupational diversity
  • No. 239 – Birthplace diversity
  • No. 284 – Age diversity
  • No. 343 – Worker-class diversity

Embracing diversity is not only good for local communities, it's also beneficial for the economy, the report says.

"Not only have waves of immigration changed the face of the nation, they’ve also brought in fresh perspectives, skills, and technologies to help the U.S. develop a strong adaptability to change," the report's author wrote. "Economies generally fare better when they openly embrace and capitalize on new ideas. Conversely, those relying on old ways and specialized industries tend to be hurt more by changes in the market."

Houston is a repeat performer: It slipped one spot from its 2024 ranking, and previously topped the overall list in 2021 — showing that the city has consistently maintained in diversity over the years.

Other diverse Texas cities
Elsewhere in Texas, Arlington surpassed Houston as the No. 4 overall most diverse city, and took the No. 1 spot in the "large city" category.

Dallas ranked just outside the top 10 this year, landing in 11th place after previously ranking eighth overall in 2024. Dallas also appeared in sixth place in the national rankings for the most diverse large cities, so the city still has some catching up to do.

Fort Worth fell into No. 25 overall this year, in a three-place slip from last year's ranking. The city performed the best in the overall categories for socioeconomic and cultural diversity, earning a respective No. 58 and No. 61.

The top 10 most diverse cities in America in 2025 are:

  • No. 1 – Gaithersburg, Maryland
  • No. 2 – Silver Spring, Maryland
  • No. 3 – Germantown, Maryland
  • No. 4 – Arlington, Texas
  • No. 5 – Houston, Texas
  • No. 6 – New York, New York
  • No. 7 – Charlotte, North Carolina
  • No. 8 – Jersey City, New Jersey
  • No. 9 – Danbury, Connecticut
  • No. 10 – Los Angeles, California
---

A version of this story originally appeared on our sister site, CultureMap.com.

View All Listings